ClinicalTrials.Veeva

Menu

Outcomes Of Interventional Catheterization In Infants Less Than 3 Months With Critical Congenital Heart Disease (CHD)

Y

YHAlattar

Status

Not yet enrolling

Conditions

Critical Congenital Heart Disease

Treatments

Procedure: cardiac catheterization

Study type

Observational

Funder types

Other

Identifiers

NCT05351125
catheterization in CHD

Details and patient eligibility

About

Congenital heart disease is the most common birth defect affecting mostly 1 in 100 births(1), critical congenital heart disease is when there is low systemic cardiac output which requires urgent surgery or catheter intervention in the first year of life(2), in low-income countries CCHD is associated with severe high mortality rate due to low health resources, in high-income countries, CCHD is associated with life-long morbidities and a high burden on the health care systems(1-3)

Full description

CCHD are classified into three major components:

Left heart obstructions representing 30-40%, complete transposition of the great arteries (mostly 30%), and right heart obstructions (20-30%).

CCHD may present with signs of low cardiac output and hypoperfusion in case of duct dependent systemic circulation or central cyanosis not responding to oxygen in duct dependent pulmonary circulation or two parallel circulations.

Critical congenital heart disease is classified into :

  • Congenital heart disease with duct-dependent systemic blood flow (SBF) as:

    1. Critical aortic stenosis
    2. Critical coarctation of the aorta
  • Congenital heart disease with duct-dependent pulmonary blood flow (PBF) as:

    1. Critical pulmonary stenosis.
    2. Pulmonary atresia with intact septum.
    3. Severe types of Fallot's tetralogy and pulmonary atresia with VSD.
  • Complete transposition of the great arteries (d-TGA) Classified as non-mixture or inadequate shunting at atrial, ventricular, or duct level.

Recent advances in percutaneous neonatal cardiac interventions have improved survival, decreased morbidity, and mortality in newborns with CCHD compared with surgery(4).

Pediatric cardiac catheter interventions have been an established way for the management of CCHD(5).

Balloon atrial septestomy is the standard intervention for patients with D-TGA with ineffective mixing (6), BAS is indicated when there is time lag between diagnosis and arterial switch operation due to transportation and lack of competent surgical team, and it is also indicated in patients with d-TGA with restrictive inter-atrial communication(7).

Ductus arteriosus stenting is used to maintain a reliable source of pulmonary blood flow in patients with duct-dependent cyanotic CHD(5).

The main advantage of ductus arteriosus stenting is the avoidance of surgery and shunt-related side effects , also it promotes significant PA growth compared to a BT shunt alone (8).

Balloon aortic and pulmonary valvuloplasty and balloon coarctation angioplasty are now established procedures for the management of patients with critical pulmonary or aortic stenosis(9).

Enrollment

40 estimated patients

Sex

All

Ages

12 hours to 3 months old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

  • All infants less than 3 months of age with critical congenital heart disease requiring urgent cardiac catheter intervention including

    1. Critical valvular aortic stenosis requiring aortic valvuoplasty.

    2. Pulmonary valvuloplasty for critical valvular pulmonary stenosis.

    3. Pulmonary valvuloplasty in pulmonary atresia with intact IVS after exclusion of RV-dependent coronary circulation.

    4. PDA stenting in duct dependent congenital cyanotic heart disease.

    5. Atrial septostomy to enhance atrial mixing (in transposition of great arteries with restrictive or no inter-atrial communication).

    6. Balloon angioplasty of native coarctation as a palliative measure to stabilize a patient with severely depressed ventricular function.

      Exclusion Criteria:

    <!-- -->
    1. patent ductus arteriosus closure
    2. percutaneous temporary pacemaker implantation for arrhythmia
    3. diagnostic catheterization.
    4. prematurity
    5. low birth weight
    6. bleeding diathesis
    7. sepsis.

Trial contacts and locations

0

Loading...

Central trial contact

Yomna Hussein Mohammed Hussein Alattar H Alattar, assisstant lecturer; Khaled A Sanousy, professor

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems